Previous 10 | Next 10 |
home / stock / ortif / ortif news
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES $500,000 AXELYS GRANT TO ADVANCE ORTHO-M DEVELOPMENT FOR MENISCUS REPAIR Canada NewsWire Meniscus indication confirms proprietary technology platform multi-indications potential Grant to accelerate development of sec...
Ortho Regenerative Technologies press release (OTCQB:ORTIF): FY GAAP EPS of -C$0.14. Cash Balance of C$314K as of January 31, 2022 For further details see: Ortho Regenerative Technologies; GAAP EPS of -C$0.14
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FOURTH QUARTER AND 2022 YEAR-END RESULTS Canada NewsWire Phase I/II clinical trial IND application cleared by FDA for testing ORTHO-R in combination with PRP for rotator cuff tear repair ORTHO-R / PRP combination be...
Ortho Regenerative Technologies (OTCQB:ORTIF) said the U.S. Patent and Trademark Office (USPTO) issued a patent related to the company's ORTHO-R soft tissue repair platform. The company said the US Patent Application No. U.S. 11,285,100 B2 titled, 'Freeze-Dried Polymer Compositions for m...
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT FOR ORTHO-R SOFT TISSUE REPAIR PLATFORM Canada NewsWire New patent issued by U.S. Patent and Trademark Office to protect core IP until 2035 Positions Company as leading player...
ORTHO REGENERATIVE TECHNOLOGIES CLOSES OVERSUBSCRIBED NON-BROKERED PRIVATE PLACEMENT FOR $3.2 MILLION Canada NewsWire Proceeds to be used to accelerate the ORTHO-R Phase I/II US Clinical trial for rotator cuff tear repair Insiders contribute approxima...
ORTHO REGENERATIVE TECHNOLOGIES TO PARTICIPATE IN THE 2022 VIRTUAL GROWTH CONFERENCE PRESENTED BY MAXIM GROUP LLC AND HOSTED BY M-VEST Canada NewsWire MONTREAL , March 24, 2022 /CNW Telbec/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTI...
ORTHO REGENERATIVE TECHNOLOGIES AMENDS THE TERMS OF ITS $3 MILLION NON-BROKERED PRIVATE PLACEMENT OF UNITS Canada NewsWire MONTREAL , March 21, 2022 /CNW/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) (" Ortho " or the " Company "), ...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES EXECUTIVE LEADERSHIP CHANGES Canada NewsWire Philippe Deschamps appointed President and CEO First patient enrolment into the U.S. ORTHO-R Phase I / II clinical trial still imminent. MONTREAL , ...
Ortho Regenerative Technologies (OTCQB:ORTIF) announced Friday a private placement offering of C$3M units priced at C$0.30 each. The company said proceeds will be used for the ORTHO-R Phase I/II US Clinical trial, and general corporate purposes. Each unit comprises of 1 common share and 1 sha...
News, Short Squeeze, Breakout and More Instantly...
Ortho Regenerative Technologies Inc Company Name:
ORTIF Stock Symbol:
OTCMKTS Market:
Ortho Regenerative Technologies Inc Website:
(NewsDirect) ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,0...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES CORPORATE NAME CHANGE TO CHITOGENX Canada NewsWire New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics MONTREAL , Sept. 7, 2022 /CNW Telbec/ ...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Canada NewsWire First patient surgery completed; additional surgeries already scheduled 8 clinical centres now fully initi...